The emergence of GLP‐1 receptor agonists has revolutionised the therapeutic landscape for IIH, offering a novel approach that addresses both the metabolic and neurological aspects of the disease [1, 2]. This evidence concerns the gene GLP1R and pseudotumor cerebri.